Full text is available at the source.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may increase the risk of residual gastric content during medical procedures.
- GLP-1 RAs are commonly used for treating type II diabetes and obesity.
- These medications can lead to an increased risk of regurgitation and aspiration due to residual gastric content.
- Patients with preexisting conditions such as gastroparesis may be at greater risk when using GLP-1 RAs.
- Guidelines and recommendations for managing perioperative risks associated with GLP-1 RAs are discussed.
Simplified